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he Annual Scientific Session of the American College of Cardiology, held in
Chicago from March 29 to April 1, 2008, provided a forum for discussion of
many current topics of interest to cardiothoracic surgeons. This review pro-
vides a brief overview of some of the most innovative and important developments
from the scientific session.
Coronary Stents
Evidence of Drug-eluting Stent Safety
A variety of conflicting reports regarding the long-term safety of drug-eluting stents
(DES) have been released during the past 24 months. The data presented at the Amer-
ican College of Cardiology Scientific Session, however, supported the overall safety
of DES compared with bare metal stents (BMS) on the basis of several randomized
trials and large observational registries. Of particular interest was the analysis of
the Massachusetts angioplasty registry exploring the use and outcomes of patients
treated with coronary stents for acute myocardial infarction between 2003 and
2004. The researchers found that in 5258 matched patients, those treated with DES
had lower rates of 2-year mortality, reinfarction, and repeat revascularization com-
pared with patients treated initially with BMS.1
Role of Drug-eluting Stents in Treatment of Multivessel and Left Main
Coronary Artery Disease
Optimizing revascularization strategies for patients with complex multivessel coro-
nary artery disease continues to be an area of intense research interest for the cardio-
vascular community. The experience of Emory University’s novel program of hybrid
revascularization for patients with complex multivessel coronary artery disease using
endoscopic atraumatic off-pump coronary artery bypass combined with DES treat-
ment of non-left anterior descending artery disease was reviewed. A total of 91 pa-
tients were treated under the hybrid protocol with impressive 12-month clinical
outcomes including only 1 mortality (1.1%) and 5 patients (5.5%) requiring a repeat
percutaneous coronary intervention. The investigators concluded that this technique
may offer optimal revascularization outcomes with minimal postoperative recovery
time, but a larger experience is required.2
The role of stents for the treatment of left main coronary artery diseasewas reviewed
with the presentation of the 3-year outcomes of theMAIN-COMPARE registry of cor-
onary DES treatment versus coronary bypass surgery in Korea. This large registry in-
cluded more than 1100 patients with complex left main bifurcation lesions, in whom
there were no significant differences in death, myocardial infarction, or stroke between
the patients treated with DES and the patients who underwent coronary artery bypassiovascular Surgery c July 2008
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CABG 5 coronary artery bypass grafting
LDL 5 low-density lipoprotein
grafting (CABG). However, there was a significantly lower
rate of repeat revascularization at 3 years in the patients
who underwent surgery.3 The role of percutaneous interven-
tion versus surgery in the treatment of 3-vessel and left main
coronary disease is the subject of the 2 large international ran-
domized trials, the SYNTAX trial SYNTAX Study: SYN-
ergy Between PCI With TAXUS and Cardiac Surgery, and
the FREEDOM trial FREEDOM - Future Revascularization
Evaluation in Patients With Diabetes Mellitus: Optimal Man-
agement of Multivessel Disease (FREEDOM), both of which
are expected to have preliminary results available in the next
24 months.
Catheter-based Treatment for Valvular Heart Disease
Preliminary Safety and Efficacy Results for Catheter-
based Aortic Valve Replacement Technologies
The treatment of calcific aortic stenosis using catheter-based
aortic valve stented prostheses was an area of great interest at
the meeting, and the results of the first 216 patients who were
treated with the Edwards Sapien pericardial valve (Edwards
Lifesciences, Irvine, Calif) via the transfemoral route were re-
ported as an interim update. These high-risk patients had
a mean age of 83.2 years and an aortic valve area of 0.60
cm2. Procedural success was achieved in 88% of patients
(successful implant), with a 12-month survival of 74%. The
mean aortic gradient was reduced from 48 mm Hg to less
than 15 mm Hg, with minimal residual aortic insufficiency.
These hemodynamic results were durable to 12 months.
However, 14.8% of the patients had a vascular complication
because of the relatively large delivery catheter (21F). The
Edwards system is currently undergoing a randomized trial
in the United States, the PARTNER study THE PARTNER
TRIAL: Placement of aortic transcatheter Valve Trial Ed-
wards SAPIEN Transcatheter Heart Valve, which includes
a high-risk surgical cohort, with subjects randomized to re-
ceive the device or surgical aortic valve replacement, as
well as a nonoperative cohort. Included in the PARTNER
study is a transapical catheter approach to be used in those
patients in whom femoral access is not feasible.
A second device for catheter-based aortic valve replace-
ment therapy, the CoreValve (CoreValve Inc, Irvine, Calif),
a self-expanding stented pericardial valve system, has been de-
ployed in more than 540 patients worldwide. This 18F diame-
ter system led to a 1% rate ofmajor vascular complications and
similar improvement in hemodynamics comparedwith theEd-
wards system, but was associated with permanent pacemaker
implantation in 13% to 24% of patients. The 30-day mortality
for the CoreValve system was 17% in these very high-riskThe Journal of Thorpatients (average EuroScore of 24), with a cardiac mortality
of 9% at 30 days. This system has received Conformite´
Europe´enne Mark approval and is currently only available
outside of the United States.4 Although the 12-month results
are promising for both transcatheter aortic valve replacement
technologies, these first-generation devices have unknown
valve durability. The results of the pivotal randomized trial
of the Edwards valve will be critical to determine the role of
this technology in future clinical practice.
Preliminary Results of Percutaneous Edge-to-Edge
Clip Repair for Functional Mitral Regurgitation
Another area of interest was the varied approaches to cathe-
ter-based treatment of mitral regurgitation. Early testing of
percutaneous annular reduction technologies was reviewed,
including strategies using the coronary sinus approach or di-
rect ventricular or atrial suturing methods. The interim results
of the EVEREST trial EVEREST - A Study of the Evalve
Cardiovascular Valve Repair System Endovascular Valve
Edge-to-Edge REpair STudy (EVEREST II) for the evalua-
tion of the edge-to-edge mitral repair procedure using the Mi-
traClip technology (eValve Incorporated, Irvine, CA)
mimicking the Alfieri repair, were reviewed for patients
with functional mitral regurgitation. The procedure, which
involves a transseptal approach to the position and deploy-
ment of the nitinol clip without associated annuloplasty,
has been performed in more than 300 patients with 3 to 41
mitral regurgitation with associated A2-P2 malcoaptation,
as part of the EVEREST trials. Of these patients, 23 had
pure functional mitral regurgitation, 19 of whom underwent
successful clip implantation. In these patients, there was a sig-
nificant reduction in mitral regurgitation to less than grade 2
in 74% of patients, and reduction in ventricular dimensions
associated with significant improvement in functional class
at 12 months follow-up. There were no clip embolizations,
and 83% of patients remained free of mitral surgery after
12 months.5 However, the small sample size and lack of
physiologic preservation of the mitral valve architecture re-
main areas of concern for this technique. The results of the
randomized EVEREST II study, expected in the next 18
months, will clarify the role of this technology relative to sur-
gical mitral valve repair.
Outside of the data available for transcatheter aortic and
mitral valve therapies, preliminary results were reviewed in
other areas of transcatheter structural heart disease ap-
proaches. Among these were ongoing trials for stents and
stent-grafts for the primary transcatheter treatment of aortic
coarctation (COAST trial COAST - Coarctation Of the Aorta
Stent Trial), continuing enrollment updates in the prevention
of stroke with transcatheter closure of patent foramen ovale
(CLOSURE CLOSURE II Trial - A Prospective, Multicen-
ter, Randomized Controlled Trial to Evaluate the Safety
and Efficacy of the STARFlex Septal Closure System Ver-
sus Best Medical Therapy in Patients With a Stroke and/oracic and Cardiovascular Surgery c Volume 136, Number 1 245
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bolism Through a Patent Foramen Ovale and RESPECT
RESPECT Trial - Patent Foramen Ovale Closure With the
AMPLATZER PFO OCCLUDER in Patients With Recur-
rent Cryptogenic Stroke Due to Presumed Paradoxical Em-
bolism Through a Patent Foramen Ovale), and transcatheter
occlusion of the left atrial appendage in the nonpharmaco-
logic management of atrial fibrillation (WATCHMAN trial
- WATCHMAN Left Atrial Appendage System for Embolic
protection in Patients With Atrial Fibrillation). The results of
these important trials will become available during the next
12 to 36 months.
Coronary Artery Disease Pharmacology
Lack of benefit of Ezetimibe in the Ezetimibe and
Simvastatin in Hypercholesterolemia Enhances
Atherosclerosis Regression Trial
Most controlled trials of lipid-lowering therapy have shown
significant reductions in cardiovascular events that correlate
tightly with the degree of achieved low-density lipoprotein
(LDL) reduction.7 Ezetimibe, a novel cholesterol-lowering
compound, selectively inhibits dietary cholesterol absorption
and, in combination with statins, provides significant incre-
mental reductions in LDL cholesterol levels. The Ezetimibe
and Simvastatin in Hypercholesterolemia Enhances Athero-
sclerosis Regression trial6 sought to determine whether the
combination of ezetimibe and simvastatin could reduce pro-
gression of atherosclerosis in patients with familial hypercho-
lesterolemia relative to high-dose simvastatin alone. During
2 years of observation in 720 patients in this study, despite
an incremental 16.5% reduction in LDL among ezetimibe-
treated patients, there was no difference in the primary
outcome of change in carotid artery intimal mean thickness
between the 2 treatment groups. Because the rate of intimal
mean thickness progression is historically a good correlate
of cardiovascular events, this study raises concern that the
lowering of LDL cholesterol with ezetimibe may not be clin-
ically beneficial. Although definitive data regarding the clin-
ical efficacy of ezetimibe await the results of ongoing trials,
such as IMPROVE-IT (expected in 2011 IMPROVE-IT -
(IMProved Reduction of Outcomes: Vytorin Efficacy Inter-
national Trial), the Ezetimibe and Simvastatin in Hypercho-
lesterolemia Enhances Atherosclerosis Regression trial
results caution physicians treating patients with cardiovascu-
lar disease to first optimize the dosing of statins tomeet guide-
line-based LDL targets and then to add drugs with proven
clinical benefits (nicotinic acid, fibrates, and bile-acid seques-
trants) for those who fail to achieve target with statins alone.
Benefits of Intensive Antiplatelet Therapy in Acute
Coronary Syndromes
A secondary analysis of patients undergoing intracoronary
stenting during an acute coronary syndrome after randomiza-
tion in the TRITON TIMI-38 trial TRITON-TIMI-38 - A246 The Journal of Thoracic and Cardiovascular Surgery c JuComparison of Prasugrel and Clopidogrel in Acute Coronary
Syndrome Subjects Who Are to Undergo Percutaneous Cor-
onary Intervention of Prosugrel (a potent thienopyridine)
versus Clopidogrel was presented. This analysis revealed
that treatment with prosugrel was associated with a signifi-
cant reduction in the rate of stent thrombosis (prosugrel
0.88% vs clopidogrel 2.03%, hazard ratio 0.42, P , .0001)
independently of the type of stent used (BMS vs DES).8
The clinical implication from this analysis is the likelihood
that if prosugrel is approved for use in the United States, it
will likely become a front-line agent in the prevention of
stent-associated thrombosis for patients with acute coronary
syndrome.
Lack of Benefit of MC-1 in Ischemia-Reperfusion
Injury
The results of the MEND-CABG I trial MEND-CABG I-A
Randomized, Double-Blind, Placebo-Controlled, Dose-
Ranging, Multi-Center Study to Evaluate the Cardiovascular
and Cerebrovascular Effects of MC-1 in Patients Undergoing
High-Risk Coronary Artery Bypass Graft (CABG) Surgery
suggested potential benefit of MC-1 (pyridoxal-50-phos-
phate, a purinergic P2-receptor antagonist that reduces intra-
cellular calcium influx) in reducing perioperative myocardial
infarction among patients undergoing CABG. However, the
MEND-CABG II,9 a pivotal, phase-3, placebo-controlled
trial of MC-1 (250 mg/d, administered immediately before
and 30 days after surgery) among 1519 patients undergoing
CABG, revealed no difference in the primary end point of
cardiovascular death or nonfatal myocardial infarction at 30
days. MC-1 therefore joins the list of agents that fail to affect
reperfusion injury after CABG.
New Treatment for Acute Heart Failure
The HORIZON-HF trial HORIZONHF - A Phase II Study to
Assess the Hemodynamic Effects of Istaroxime, a Novel Lu-
sinotropic Agent, in Patients Hospitalized With Worsening
Heart Failure and a Reduced Left Ventricular Systolic Func-
tion10 randomized 120 patients with a left ventricular ejection
fraction# 35% and acute decompensated heart failure stabi-
lized with conventional medical therapy to a 6-hour infusion
of istaroxime or placebo. In this dose-ranging study, istarox-
ime administration was associated with a rapid, sustained de-
crease in pulmonary capillary wedge pressure and
improvement in some measures of systolic and diastolic
function. In contrast with many currently available inotropic
agents, the observed improvements in cardiac function seen
with istaroxime were associated with an increase in systolic
blood pressure and a decrease in heart rate. Whether these
differential hemodynamic effects will be replicated in pa-
tients with more advanced acute decompensated heart failure
and low cardiac output or will translate to meaningful im-
provements in clinical outcomes remains a subject for future
study.ly 2008
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